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Abstract
Background: Clinical studies suggest that 10-50% of patients are resistant to clopidogrel therapy. ADP induced
platelet aggregation, a widely used test to monitor clopidogrel therapy, is affected by aspirin and is not specific for the
P2Y12 receptor inhibited by clopidogrel.
Objectives: To develop a P2Y12-specific platelet aggregation test and to compare it with other methods used for
monitoring clopidogrel therapy.
Patients/Methods: Study population included 111 patients with the history of ischemic stroke being on clopidogrel
monotherapy and 140 controls. The effect of clopidogrel was tested by a newly developed ADP(PGE1) aggregation
test in which prostaglandin E1 treated platelets are used. Results of conventional ADP induced platelet aggregation,
VerifyNow P2Y12 assay and ADP(PGE1) aggregation were compared to those obtained by flow cytometric analysis
of vasodilator stimulated phosphoprotein (VASP) phosphorylation. Reference intervals for all assays were
determined according to the guidelines of Clinical Laboratory Standards Institute.
Results: The P2Y12-specificity of ADP(PGE1) test was proven by comparing it with ADP aggregation in the
presence of P2Y1 antagonist, adenosine 3’, 5’-diphosphate. The method was not influenced by aspirin treatment.
Approximately 50% of patients were clopidogrel resistant by conventional ADP aggregation and VerifyNow tests. The
ADP(PGE1) method and the VASP phosphorylation assay identified 25.9% and 11.7% of patients as non-
responders, respectively. ADP(PGE1) aggregation showed good correlation with VASP phosphorylation and had
high diagnostic efficiency.
Conclusion: The new ADP(PGE1) method is a reliable test for monitoring P2Y12 receptor inhibition by platelet
aggregation. As a subset of patients are non-responders, monitoring clopidogrel therapy by adequate methods is
essential.
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Introduction
Clopidogrel, an irreversible inhibitor of platelet P2Y12 ADP
receptor, is widely used as monotherapy or in combination with
aspirin to reduce the risk of recurrent atherothrombotic
ischemic events [1]. Clopidogrel is a pro-drug; its active
metabolite is produced by the liver in a multistep process. The
active metabolite covalently binds to the P2Y12 receptor and
thereby inhibits the amplification mechanism of ADP-induced
platelet activation and aggregation. Despite its potent
antiplatelet effect, clinical studies suggest that approximately
10-50% of patients are resistant to therapy and it is not clear,
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which laboratory test is most suitable to identify such patients
[2–5]. A number of methods are available for monitoring the
effect of clopidogrel. For the time being, ADP-induced platelet
aggregation, the most commonly used method, is considered
as the gold standard [4,6,7]. One major drawback of this
method is that it is not specific for P2Y12 receptor inhibition
and aspirin therapy influences its effect. Despite this fact, most
studies on clopidogrel resistance include patients on combined
antiplatelet therapy (aspirin+clopidogrel) and only few reports
are available on patients taking clopidogrel as monotherapy.
Other methods, which are specific for P2Y12 receptor
inhibition, such as the flow cytometric assay of vasodilator
stimulated phosphoprotein (VASP) phophorylation and the
VerifyNow P2Y12 tests are relatively expensive and require
special instrumentation. A common problem with all of these
methods is the lack of consensus cut-off values for identifying
clopidogrel non-responders, which makes the interpretation of
the data ambiguous [4].
In this study, we had three major aims: 1/ to develop and
validate a P2Y12 receptor specific ADP aggregation test for the
detection of clopidogrel’s effect, 2/ to determine reference
intervals for different methods used to evaluate the effect of
clopidogrel, 3/ to compare the results of these laboratory tests
obtained in patients receiving clopidogrel monotherapy.
Patients and Methods
Patient and control population
Study population included 114 patients with the history of
non-cardiogenic ischemic cerebrovascular disease being on 75
mg/day clopidogrel therapy for at least one month and 140 sex-
matched healthy controls not taking any medication influencing
platelet function. A priori exclusion criteria were: aspirin/non-
steroid anti-inflammatory drug therapy, chronic liver disease,
hemoglobin concentration <80 g L-1, platelet count >500×109 L-1
or <150×109 L-1, acute infectious disease/antibiotic treatment,
qualitative defects of platelet function or other types of
hemorrhagic diathesis, major surgical procedure or major
ischemic event within one month of enrollment, admitted non-
compliance. In the case of non-responders the possibility of
non-compliance during the study was investigated by an oral
interview. Whenever non-compliance was suspected,
measurements were repeated after a two-week period of drug
administration. Due to proven non-compliance three patients
were excluded from the study. Baseline characteristics of
patients and controls are shown in Table 1.
Ethics statement
The study protocol was approved by the Scientific and
Research Ethics Council of the Hungarian Ministry of Health
(permission no. 8-281/2009-1018EKU). Written informed
consent was obtained from all study participants.
Blood sampling
Blood drawing was performed by venipuncture from an
antecubital vein after overnight fasting. For light transmission
aggregometry and VASP phosphorylation assay blood samples
were collected into Vacutainer tubes containing 0.109 mol/L
trisodium citrate (Becton-Dickinson, Franklin Lakes, NJ). For
VerifyNow P2Y12 assay blood was collected into Vacuette tube
(Greiner Bio-One, Basel, Switzerland). After blood drawing the
VerifyNow P2Y12 assay, light transmission aggregometry and
VASP phosphorylation test were performed within 1, 4 and 24
hours, respectively.
Light transmission aggregometry and ATP release
ADP-induced platelet aggregation and secretion was
monitored using a Chrono-Log model 700 lumiaggregometer
(Chrono-Log Corporation, Havertown, PA). Citrate-
anticoagulated whole blood was centrifuged at 150 g for 15 min
at room temperature to obtain platelet rich plasma (PRP). After
carefully removing the upper two third of PRP, tubes were
further centrifuged at 1500 g for 20 min to obtain platelet poor
plasma (PPP). Platelet count was adjusted by the addition of
the required amount of PPP, to obtain a platelet count of
250×109 L-1. Baseline optical density was set on PPP.
Aggregation induced by 5 µM and 20 µM ADP (Helena
Laboratories, Beaumont, TX) was monitored for 6 min.
Luciferin-luciferase reagent (Biothema AB, Handen, Sweden)
was added to each sample for the measurement of ATP
release from platelet delta granules. Maximal percentage
aggregation (maximal Δtransmission %) and ATP release
(μmol ATP/1011 platelets) were recorded for each sample.
P2Y12 specific ADP(PGE1) platelet aggregation test
Conventional ADP-induced platelet aggregation was
modified in order to obtain P2Y12 receptor specific platelet
aggregation. In this case PRP was pre-incubated with 0.31 µM
prostaglandin E1 (PGE1; Sigma-Aldrich) for 3 min at 37 °C
prior to ADP-induced aggregation to suppress the undesirable
Table 1. Characteristics of patients and controls.
 Patients Controls  
Number 111 140  
Male gender 53 (47.7%) 68 (48.5%) p=0.89
Age (years) 61.6±10.4 43.3±18 p<0.001
BMI (kg m-2) 25.97±7.9 24.03±3.79 p<0.001
 Diabetes mellitus 22 (20%)   
History of hypertension 80 (72%) 10 (7.1%) p<0.001
Dyslipidemia 73 (65.7%) 2 (1.4%) p<0.001
Current smoker 24 (21.6%) 34 (24.2%) p=0.64
 Previous MI 24 (21.6%)   
 History of multiple stroke/TIA 83 (74.7%)   
 PPI use 11 (9.9%)   
 Statin use 67 (60%)   
 Duration of clopidogrel therapyin months (median; range 12; 1-119   
BMI, body mass index; MI, myocardial infarction; PPI, proton pump inhibitor.
Continuous data are presented as means ± standard deviation when normally
distributed (age and BMI), statistical analysis was performed using Student’s t test.
Duration of clopidogrel therapy showed non-parametric distribution and is
expressed as median and range. Categorical variables are presented as counts
(%); in this case differences between groups, where applicable, were tested by the
χ2 test.
Novel P2Y12 Specific Platelet Aggregation Test
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contribution of P2Y1 receptors. The extent of P2Y1 receptor
suppression by PGE1 was compared to the effect of P2Y1
antagonist adenosine 3’, 5’-diphosphate (A3P5P; Sigma-
Aldrich) [8]. In preliminary experiments, modified ADP-induced
platelet aggregation was carried out using 20 µM, 40 µM and
60 µM ADP: optimal aggregation was observed with 40 µM or
60 µM ADP; 40 µM ADP was used throughout the study. The
effect of aspirin treatment on the results was tested on 50
subjects being on 100 mg/day aspirin monotherapy.
VerifyNow P2Y12 assay
The VerifyNow P2Y12 assay (Accumetrics, San Diego, CA)
is a whole blood point-of-care test [9], which measures the
ADP-induced co-agglutination of platelet and fibrinogen-coated
beads in the presence of PGE1. The presence of PGE1 makes
the test specific for the P2Y12 receptor pathway. In the assay
ADP-activated platelets bind to fibrinogen-coated beads and
agglutinate them. The instrument measures the change in light
transmittance and reports results as P2Y12 reaction units
(PRU). In addition, the device calculates the percentage of
P2Y12 inhibition, based on thrombin receptor-activating
peptide (TRAP)-induced platelet aggregation. However, in most
publications the results are expressed as PRU.
Flow cytometric analysis of vasodilator-stimulated
phosphoprotein (VASP) phosphorylation
The VASP phosphorylation assay was carried out according
to the manufacturer’s instructions using a commercially
available kit from Biocytex (Marseille, France). The test is
based on the fact that in the presence of PGE1 and ADP, the
extent of VASP phosphorylation is proportional to the inhibition
of platelets by clopidogrel [10]. Briefly, samples of citrate-
anticoagulated blood were incubated with either PGE1 or
PGE1+ADP and fixed in paraformaldehyde. Platelets were then
permeabilized, labeled with a CD61 phycoerythrin-labeled
platelet specific antibody and a FITC-labeled phosphorylated
VASP (VASP-P) specific mouse monoclonal antibody or a
negative isotype control antibody. Samples were analyzed on a
FacsCalibur flow cytometer (Becton Dickinson, Franklin Lakes,
NJ). Geometric mean fluorescence intensity (MFI) values were
determined in the presence of PGE1 without or with the
addition of ADP. The extent of VASP phosphorylation was
expressed as platelet reactivity index (PRI) calculated from the
MFI values (after deduction of MFI obtained with isotype
control) using the following formula:
PRI(%)=100×[MFI(PGE1) -MFI(PGE1+ADP)]/MFI(PGE1)
Determination of reference intervals and statistical
analysis
Statistical analysis was performed using GraphPad Prism
Software (La Jolla, CA). For all methods the reference interval
corresponding to the 99% central interval was determined
according to the guidelines of Clinical Laboratory Standards
Institute (CLSI) [11]. The lowest value of the reference interval
was used as the diagnostic cut-off: those patients, who were on
clopidogrel therapy and had results within the reference interval
were considered non-responders to the therapy. Data obtained
by different methods were correlated according to Spearman’s
rank correlation method. Differences between patients and
controls were analyzed using the Mann-Whitney test, p < 0.05
was considered as significant. In the case of categorical
variables differences between groups were tested with the χ2
test. The results of different methods on clopidogrel-treated
patients were compared to those obtained by the VASP assay
by calculating coefficients of determination (r2) and diagnostic
efficiencies (DE). In the latter case the sum of results identical
by the VASP and the other investigated assay, i.e., responders
by both assays plus non-responders by both assays, was
divided by the number of investigated patients. DE was
expressed as percentage.
Results
P2Y12 specific ADP(PGE1) aggregation test
Figure 1 demonstrates representative aggregation curves
obtained with the ADP(PGE1) aggregation test and with the
conventional ADP induced aggregation method. In case of a
clopidogrel responder patient, residual transient aggregation
was observed with the conventional ADP induced platelet
aggregation method, due to the activation of P2Y1 receptor.
When the PRP sample was pretreated with PGE1 the
aggregation curve lacked the shape change signal and
effective clopidogrel treatment completely abrogated ADP-
induced aggregation. Aggregation of platelets from clopidogrel
non-responder patients was comparable to that of control
platelets. The effect of PGE1 pretreatment highly correlated
(r=0.89, p=0.001) with that of the P2Y1 antagonist, A3P5P
(Figure 2) demonstrating that the addition of PGE1 abolished
signaling through the P2Y1 receptor. Another problem in
testing the effect of clopidogrel by conventional ADP induced
aggregation is its inhibition in patients on aspirin therapy. For
this reason this test can hardly be used for testing the effect of
clopidogrel on patients being on dual therapy. In contrast, the
results of ADP(PGE1) aggregation obtained on PRP of controls
and patients on aspirin monotherapy showed no difference
(Figure 3).
Results of testing patients on clopidogrel monotherapy
by different laboratory methods.  Cut-off values for
clopidogrel non-responsiveness, corresponding to the lower
limits of reference intervals, were: 39.5% maximal aggregation
induced by 5 µM ADP, 56.8% maximal aggregation induced by
20 µM ADP, 220 PRU measured by the VerifyNow P2Y12
assay, 72% PRI as determined by the VASP phosphorylation
test and 9.1% maximal aggregation induced by the
ADP(PGE1) aggregation method (Figures 4-6). Based on these
cut-off values the ratio of clopidogrel non-responders varied
between 12–54% depending on the method used.
Approximately half of the patients were identified as non-
responders by the traditional ADP aggregation method (50.5%
using 5 µM and 51.4% using 20 µM ADP as agonist) (Figure
4). In the control group the results of ADP-induced ATP release
scattered in a wide range (0-2.46 µmol ATP/1011 platelets with
5 µM ADP and 0.06-2.69 µmol ATP/1011 platelets with 20 µM
ADP) including some very low secreted ATP values (data not
shown). For this reason this method cannot be considered as
the test for measuring the effect of clopidogrel.
Novel P2Y12 Specific Platelet Aggregation Test
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The ratio of non-responders diagnosed by the P2Y12
specific VerifyNow P2Y12 assay (54%) was similar to that
demonstrated by the conventional ADP aggregation method
(Figure 5A). Using the other P2Y12 specific method, the VASP
phosphorylation test, somewhat different results were obtained
(Figure 5B). In this case the results of patients showed a wide
distribution. Using the reference interval determined according
to CLSI guidelines (72% PRI), 88.3% of the results of
clopidogrel treated patients were below this limit indicating an
effect specific to clopidogrel therapy. However, the wide
distribution of results raised the possibility that some of these
patients are not effectively protected by clopidogrel. In the past
few years, a number of clinical studies involving patients on
combined antiplatelet therapy suggested a cut-off of 50% PRI
for clinical clopidogrel resistance [4,5,12]. Applying this cut-off
to our patient population only 43.2% of patients would be in the
clinically effective range. We considered these patients as
strong responders, while patients with PRI below the reference
interval, but above 50% were defined as weak responders.
The P2Y12 specific ADP(PGE1) platelet aggregation method
was also tested on the study population (Fig. 6). Using this test,
28.8% of patients were identified as non-responders, i.e. their
results were in the range of the control population. In 39.7% of
patients no aggregation was observed, this group of patients
was tentatively considered as strong responders, while 31.5%
of the patients demonstrated impaired (< 9.1%), but detectable
aggregation (weak responders).
Figure 1.  Representative ADP aggregation curves demonstrating the effect of clopidogrel treatment.  Platelet aggregation
was performed on PGE1 pretreated (right side) and non-pretreated (left side) platelet rich plasma (PRP). The upper and lower
panels of the figure show results with PRP from a clopidogrel responder and a non-responder patient, respectively. Aggregation
curves with samples from controls not taking antiplatelet medication are also demonstrated on each panel.
doi: 10.1371/journal.pone.0069417.g001
Novel P2Y12 Specific Platelet Aggregation Test
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Correlation and diagnostic efficiency of laboratory
tests used for the detection of clopidogrel effect
As the VASP assay is specific for P2Y12 inhibition and it was
shown to have the best correlation with the plasma level of
active metabolite [13,14], this assay was selected as the one to
which other laboratory tests were compared. Among the
investigated methods, the ADP(PGE1) aggregation assay had
the highest DE (Table 2). The best correlation was found
between the ADP(PGE1) aggregation test and VASP
phosphorylation assay (r=0.79, r2=0.62, p<0.0001; Figure 7).
The conventional ADP assays and the VerifyNow P2Y12 assay
correlated with the VASP phosphorylation assay to a lesser
extent (Table 2).
Discussion
Suboptimal inhibition of platelet function by clopidogrel in a
considerable part of the patients has been demonstrated by a
number of clinical studies [4,6,12,14–17]. To overcome the
wide inter-individual variability in the response to clopidogrel,
guided antiplatelet therapy has been suggested, which could
improve clinical outcome and may result in a reduced rate of
ischemic and hemorrhagic complications [12,18]. Tailored
treatment based on the results of laboratory tests however is
not yet adopted in routine clinical practice due to a number of
important issues: questions of efficacy, cost-benefit ratios and
lack of standardized laboratory test [14,16]. In order to monitor
therapy, it is necessary to have an easily applicable, reliable,
affordable method, which reports the specific effect of the
Figure 2.  Correlation of ADP-induced aggregation in platelet rich plasma pre-treated with PGE1 or with P2Y1
inhibitor.  Platelet rich plasma was pre-treated with 0.31 µM PGE1 or 1 mM adenosine 3’, 5’-diphosphate (A3P5P), a P2Y1
receptor inhibitor, for 3 min at 37 °C. Broken lines represent 95% confidence interval, r=0.89, p=0.001.
doi: 10.1371/journal.pone.0069417.g002
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antiplatelet drug. In addition, well established cut-off values are
required for the adequate evaluation of laboratory results.
For the time being, ADP-induced platelet aggregation is still
widely used to identify clopidogrel non-responders, although
this test is not specific for the inhibition of the P2Y12 receptor
and thus it is not optimal to test the effect of clopidogrel
[4,7,14]. Moreover, most studies on clopidogrel resistance
included patients on dual antiplatelet therapy (aspirin
+clopidogrel) although aspirin inhibits ADP-induced platelet
aggregation. This fact should always be taken into
consideration when conventional ADP-induced platelet
aggregation is used to evaluate the effect of clopidogrel in
patients on dual antiplatelet therapy. It was demonstrated that
the ADP(PGE1) method specifically detects the inhibition of
P2Y12 receptor and avoids the undesirable contribution of
P2Y1 receptor. It is to be noted that ADP aggregation, at
agonist concentrations regularly used for aggregation (1-10
µM), is abolished by the blockade of P2Y1 receptor pathway.
However, it was shown that much higher concentrations of
ADP are capable of inducing platelet aggregation, but not
shape change, in the PRP from P2Y1 knock out mice [19] and
in human PRP in which P2Y1 receptor signaling was blocked
by A3P5P [20]. Accordingly, we used 40 µM ADP in the newly
developed test. The ADP(PGE1) method is not influenced by
aspirin therapy, thus it is suitable to monitor clopidogrel
responsiveness in patients on dual antiplatelet therapy. The
test is inexpensive, relatively easy to carry out and does not
require instrumentation other than an aggregometer.
Another major problem concerning the laboratory evaluation
of clopidogrel therapy is the lack of consensus cut-off values.
There could be two different definitions, laboratory and clinical,
for the cut-off value. Non-responders defined by a laboratory
method represent clopidogrel treated patients with laboratory
results remaining in the reference interval established on
healthy controls not taking antiplatelet medication. Values
below the lower limit of reference interval prove an effect of
clopidogrel, although this effect might vary widely to include
weak to strong responses. In spite of numerous reports on
clopidogrel resistance, well-established method-specific
reference intervals for respective platelet function tests are
scarcely available. In this study, we established reference
intervals according to the guidelines of CLSI for all investigated
Figure 3.  Aspirin therapy does not influence the P2Y12 specific ADP(PGE1) platelet aggregation test.  ADP-induced
aggregation in PGE1 pre-treated platelet rich plasma of controls (solid circles) and patients on aspirin therapy (open squares).
Horizontal lines represent medians, the long broken line indicates the lower limit of reference interval. n.s.: non-significant.
doi: 10.1371/journal.pone.0069417.g003
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Figure 4.  Results of ADP-induced platelet aggregation.  Platelet aggregation was induced by 5 µM (A) and 20 µM ADP (B) in
the platelet rich plasma of controls (solid circles) and patients on clopidogrel monotherapy (open circles). Horizontal lines represent
medians, the long broken line indicates the lower limit of reference interval. NR: non-responder.
doi: 10.1371/journal.pone.0069417.g004
Figure 5.  Results of VerifyNow P2Y12 and VASP phosphorylation tests.  VerifyNow P2Y12 (A) and VASP phosphorylation (B)
tests were performed in the control group (solid circles) and in the group of patients on clopidogrel therapy (open circles). Horizontal
lines represent medians, the long broken line indicates the lower limit of reference interval, the long dotted line on panel B shows
the cut-off for clopidogrel resistance established in clinical studies [4,5,12]. NR: non-responder, WR: weak responder, SR: strong
responder.
doi: 10.1371/journal.pone.0069417.g005
Novel P2Y12 Specific Platelet Aggregation Test
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methods. The use of reference interval based laboratory cut-off
values allows the demonstration of the clopidogrel effect, but
the demonstration of such effect does not necessarily mean
effective protection against cerebrovascular events. Given the
large inter-individual variability and the number of possible
underlying mechanisms of variable platelet response to
clopidogrel (variable absorption or metabolism, CYP
polymorphisms, concomitant drug interaction, non-compliance
etc. [21,22]) it might be important to distinguish patients who
are not responding to therapy at all from patients showing
moderate effects, although the clinical relevance of weak
response to clopidogrel is yet to be determined. In several
reports, based on the extent of response to clopidogrel as
compared to pre-treatment values or to placebo controls
patients were categorized as „non-responsive“, „semi-
responsive“ and „responsive“ [23,24] or „high“, „average“ and
„low“ responders [25,26]. However, such set-ups are rarely
available in everyday clinical practice. Besides, the absolute
level of on-treatment platelet reactivity seems to be a better
measure of thrombotic risk than the change of platelet reactivity
related to pretreatment values. Based on our results,
categorization within the group of responders would be
artificial, perhaps with the exception of the ADP(PGE1)
method. In the latter case patients with complete inhibition of
platelet aggregation were considered as strong responders,
while patients showing aggregation below the reference
interval were classified as weak responders.
In the past few years, a number of studies were published in
which high on-treatment platelet reactivity was linked to
ischemic events and clinical cut-offs were determined by
receiver-operating characteristic (ROC) curves [4,12]. It should
be noted that these cut-offs most likely depend on the subset of
patients studied and to date, cut-off values have been
estimated mainly in patients undergoing percutaneous
coronary interventions (PCI). Interestingly, laboratory cut-offs
established in our study were fairly similar to those obtained by
a number of prospective studies in the case of ADP induced
platelet aggregation and the VerifyNow P2Y12 assay [4,12].
For instance, in a large, prospective, observational study,
including 1,069 consecutive patients treated with clopidogrel
following elective PCI, cut-off points were comparable to those
Table 2. Diagnostic efficiency and correlation of methods
used for the measurement of platelet inhibition by
clopidogrel.
 
Diagnostic
efficiency (%)
Coefficient of
determination (r2)
5 µM ADP induced platelet
aggregation 60.4 0.41
20 µM ADP induced platelet
aggregation 60.4 0.43
VerifyNow P2Y12 test 56.9 0.50
ADP(PGE1) platelet aggregation
method 85.6 0.62
Test results were compared to those obtained by the VASP phosphorylation assay.
Results were calculated using the percentage of maximal aggregation and PRU in
case of the platelet aggregation methods and the VerifyNow test, respectively.
Figure 6.  Results of P2Y12 specific ADP(PGE1) platelet aggregation test.  P2Y12 specific ADP aggregation test was
performed in the control group (solid circles) and in the group of patients on clopidogrel therapy (open circles). Results are
demonstrated as scatterograms (A) and histograms (B). Horizontal lines on panel A represent medians, the long broken line
indicates the lower limit of reference interval. NR: non-responder, WR: weak responder, SR: strong responder.
doi: 10.1371/journal.pone.0069417.g006
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in our study: 42.9% vs. 39.5% for maximal aggregation induced
by 5 µM ADP; 64.5% vs. 56.8% for maximal aggregation
induced by 20 µM ADP; 236 PRU vs. 220 PRU for the
VerifyNow P2Y12 assay [27]. In the case of VASP
phosphorylation assay our study indicates that patients with
results below the threshold of 72% PRI demonstrate a
response to clopidogrel therapy, although it is possible that
moderate response is unsatisfactory in a clinical setting. This
cut-off is considerably higher than the most commonly used
cut-off value based on the results of prospective studies (50%
PRI) [5]. Obviously, in addition to clopidogrel non-
responsiveness a number of other factors contribute to the
clinical outcome.
Several studies have shown relatively poor agreement
among different laboratory tests to identify clopidogrel non-
responders [28,29]. Most of these studies include patients on
dual antiplatelet therapy and only scarce reports involving
relatively few patients are available on clopidogrel
monotherapy [30,31]. In fact, it is less known how laboratory
tests correlate in patient populations not affected by aspirin
therapy. Clopidogrel as monotherapy is a first-line choice for
anti-platelet therapy in ischemic stroke patients for secondary
prevention of atherothrombotic events [32–34]. In our study, we
investigated 111 ischemic stroke patients on clopidogrel
monotherapy and compared the results of different laboratory
tests. The best correlation was found between the ADP(PGE1)
platelet aggregation test and the VASP phosphorylation assay.
The highest DE of ADP(PGE1) platelet aggregation assay also
indicates that this is a reliable test to monitor the efficacy of
clopidogrel therapy.
Insufficient control of non-compliance, which mimics non-
responsiveness, is a general limitation of such studies,
including ours. Although considerable effort was made to
detect non-compliance, it might not have been fully eliminated.
This problem might influence the percent of non-responders,
but does not influence method-to-method comparisons.
Figure 7.  Correlation of VASP phosphorylation and P2Y12 specific ADP(PGE1) aggregation tests in clopidogrel treated
patients.  Broken lines represent the lower limit of reference intervals, dotted lines separate presumed strong responders from
weak responders. NR: non-responder, WR: weak responder, SR: strong responder.
doi: 10.1371/journal.pone.0069417.g007
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Another limitation of our study could be the age difference
between the control and patient group. We were not able to
recruit sufficient number of age-matched controls not taking
drugs potentially influencing platelet function. However, as test
results did not show significant age dependence in the control
group (not shown), age discrepancy is not likely to affect the
results.
In conclusion, we have developed a new, reliable and
affordable platelet aggregation method specific for the P2Y12
receptor and thus clopidogrel therapy. It showed good
correlation with the VASP phosphorylation assay and had high
DE in patients receiving clopidogrel monotherapy. As opposed
to the conventional method, the new test is not influenced by
aspirin therapy and therefore it is most likely a reliable choice
to test patients on dual antiplatelet therapy. The value of this
new test in a clinical setting remains to be investigated in
prospective follow-up studies.
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